Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641180 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
A Phase 3 study of Influenza, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,180
- Enrollment target
- 20
- Study locations
NCT06641180: Completed Phase 3 study of Influenza, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT06641180 is a Phase 3 study of Influenza that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,180 participants, below the 36,796-participant average among 156 other Influenza trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06641180, a Phase 3 study of Influenza, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
Primary Outcome
GMTs of anti-influenza antibodies were measured using hemagglutination inhibition (HAI) assay for 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria lineage.
Conditions Studied
Interventions
- BIOLOGICAL High-Dose trivalent influenza vaccine (Split virion, Inactivated)
- BIOLOGICAL Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Study Locations (20)
Georgia
- IACT Health - Columbus - Talbotton Road- Site Number : 8400011 - Columbus
- Cenexel IRA - iResearch Atlanta- Site Number : 8400007 - Decatur
- The Hope Clinic of Emory Vaccine Center- Site Number : 8400017 - Decatur
- Centricity Research - Rincon- Site Number : 8400012 - Rincon
- Cenexel IRS - iResearch Savannah- Site Number : 8400008 - Savannah
Florida
- Alliance for Multispeciality Research - Fort Myers- Site Number : 8400019 - Fort Myers
- Research Centers of America - Hollywood- Site Number : 8400010 - Hollywood
North Carolina
- Centricity Morehead- Site Number : 8400014 - Morehead City
- Centricity New Bern- Site Number : 8400015 - New Bern
California
- CenExel CNS- Site Number : 8400005 - Los Alamitos
Kansas
- Alliance for Multispeciality Research - Newton- Site Number : 8400003 - Newton
Kentucky
- Alliance for Multispeciality Research - Lexington- Site Number : 8400002 - Lexington
Maryland
- CBH Health - Gaithersburg- Site Number : 8400004 - Gaithersburg
New Jersey
- Hassman Research Institute - Berlin- Site Number : 8400006 - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,180 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2025-06-24 |
| Phase | Phase 3 |
What the finished NCT06641180 record still lists
NCT06641180 is an interventional study that assigns participants to a tested intervention. Its 1,180 participants enrollment target places it among the larger protocols in the corpus, below the 36,796-participant average among 156 other Influenza trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which High-Dose trivalent influenza vaccine (Split virion, Inactivated) is the first listed.
NCT06641180 names 20 study sites across 14 states, led by Georgia, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06641180 about?
NCT06641180 is a clinical study titled "Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age". The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
What is the current status of trial NCT06641180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,180 participants. The study started on 2024-11-04. Estimated completion is 2025-06-24.
What conditions does trial NCT06641180 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT06641180?
The interventions under investigation include: High-Dose trivalent influenza vaccine (Split virion, Inactivated) (BIOLOGICAL), Standard-dose trivalent influenza vaccine (Split virion, Inactivated) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06641180?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641180 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06641180's enrollment target sits among peer trials
1,180 33rd of 156 higher than 124 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
-
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI